Review Article
Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac
Table 1
Comparison of the efficacy of celecoxib and etoricoxib in patients with OA.
| ||||||||||||||||||||||||||||||||||||||||||||||||
Unless indicated otherwise, all efficacy endpoints are primary (or coprimary), and all data is shown as difference in LS mean change (95% CI). Etoricoxib is at least as effective as celecoxib when the upper bound of the 95% CI < 10 mm VAS. Negative mean difference value favors etoricoxib. Secondary endpoints. OA, osteoarthritis; TWA, time-weighted average; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; VAS, visual analog scale; PGADS, Patient Global Assessment of Disease Status; OD, once daily; LS, least squares. |